NICE Technology Appraisals — August 2026 

On 6 August 2026, NICE recommended acalabrutinib (Calquence®, AstraZeneca) in two combination regimens for first-line treatment of blood cancers. Acalabrutinib plus bendamustine and rituximab was recommended for adults with untreated mantle cell lymphoma (MCL) not eligible for autologous stem cell transplant, with approximately 350 patients expected to benefit. Acalabrutinib plus venetoclax (without obinutuzumab) was recommended […]

NCPE — First National HTA Using EU Joint Clinical Assessment Data

The NCPE completed a rapid review of onasemnogene abeparvovec intrathecal (Itvisma®), Novartis’s intrathecal gene therapy for spinal muscular atrophy (SMA), making this the first national HTA assessment completed for a medicine undergoing an EU Joint Clinical Assessment (JCA) under the EU HTA Regulation. The JCA report was endorsed by the Member State Coordination Group on […]